Junning Cao

2.0k total citations
90 papers, 907 citations indexed

About

Junning Cao is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Junning Cao has authored 90 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pathology and Forensic Medicine, 53 papers in Oncology and 18 papers in Genetics. Recurrent topics in Junning Cao's work include Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (15 papers). Junning Cao is often cited by papers focused on Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (15 papers). Junning Cao collaborates with scholars based in China, United States and South Korea. Junning Cao's co-authors include Xiaonan Hong, Dongmei Ji, Fangyuan Chen, Shanhua Zou, Junmin Li, Jianmin Wang, Weiguo Su, Zhiyu Chen, Songhua Fan and Jun Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Junning Cao

81 papers receiving 892 citations

Peers

Countries citing papers authored by Junning Cao

Since Specialization

Citations

This map shows the geographic impact of Junning Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junning Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junning Cao more than expected).

Fields of papers citing papers by Junning Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junning Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junning Cao. The network helps show where Junning Cao may publish in the future.

Co-authorship network of co-authors of Junning Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Junning Cao. A scholar is included among the top collaborators of Junning Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junning Cao. Junning Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial	Clinical Drug Investigation	Dongmei Ji, Shufang Wang et al.	0
2	Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Blood	Zheng Song, Ying Cheng et al.	1
3	Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study	Cancer Medicine	Guangliang Chen, Qunling Zhang et al.	3
4	PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis	Blood Research	Yonghe Wu, Baohua Yu et al.	2
5	1208MO A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary	Annals of Oncology	Zhiguo Luo, Xin Liu et al.	2
6	Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial	The Oncologist	Junning Cao, Hongqian Guo et al.	4
7	Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.	Journal of Clinical Oncology	Emmanuel Bachy, Kerry J. Savage et al.	6
8	Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma	Annals of Nuclear Medicine	Bingxin Gu, Jiyi Hu et al.	9
9	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma	Annals of Translational Medicine	Yao Zhang, Yizhen Liu et al.	4
10	PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR	Molecular Medicine Reports	Leiping Wang, Zhonghua Tao et al.	10
11	A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy	Medicine	Dongmei Ji, Jian Zhang et al.	3
12	174P A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study	Annals of Oncology	Jun Han, Hui Wang et al.	13
13	<p>Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma</p>	Cancer Management and Research	Yizhen Liu, Yumei Liu et al.	2
14	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma	Clinical Cancer Research	Yuqin Song, Jianqiu Wu et al.	109
15	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study	Journal of Hematology & Oncology	Rui‐Hua Xu, Jin Li et al.	63
16	HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China	Medical Oncology	Zheng Wei, Shanhua Zou et al.	17
17	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors	Journal of Hematology & Oncology	Jian Zhang, Junning Cao et al.	31
18	Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group	Journal of Hematology & Oncology	Seok Jin Kim, Hyun Ae Jung et al.	55
19	Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab	Oncology Letters	Bing Cao, Xiaoyan Zhou et al.	3
20	Rituximab in treatment of primary gastric diffuse large B-cell lymphoma	Leukemia & lymphoma	Jian Zhang, Gang Li et al.	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact